Cargando…

Improved Glucose Metabolism In Vitro and In Vivo by an Allosteric Monoclonal Antibody That Increases Insulin Receptor Binding Affinity

Previously we reported studies of XMetA, an agonist antibody to the insulin receptor (INSR). We have now utilized phage display to identify XMetS, a novel monoclonal antibody to the INSR. Biophysical studies demonstrated that XMetS bound to the human and mouse INSR with picomolar affinity. Unlike mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Corbin, John A., Bhaskar, Vinay, Goldfine, Ira D., Bedinger, Daniel H., Lau, Angela, Michelson, Kristen, Gross, Lisa M., Maddux, Betty A., Kuan, Hua F., Tran, Catarina, Lao, Llewelyn, Handa, Masahisa, Watson, Susan R., Narasimha, Ajay J., Zhu, Shirley, Levy, Raphael, Webster, Lynn, Wijesuriya, Sujeewa D., Liu, Naichi, Wu, Xiaorong, Chemla-Vogel, David, Lee, Steve R., Wong, Steve, Wilcock, Diane, White, Mark L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922975/
https://www.ncbi.nlm.nih.gov/pubmed/24533136
http://dx.doi.org/10.1371/journal.pone.0088684
_version_ 1782303542457925632
author Corbin, John A.
Bhaskar, Vinay
Goldfine, Ira D.
Bedinger, Daniel H.
Lau, Angela
Michelson, Kristen
Gross, Lisa M.
Maddux, Betty A.
Kuan, Hua F.
Tran, Catarina
Lao, Llewelyn
Handa, Masahisa
Watson, Susan R.
Narasimha, Ajay J.
Zhu, Shirley
Levy, Raphael
Webster, Lynn
Wijesuriya, Sujeewa D.
Liu, Naichi
Wu, Xiaorong
Chemla-Vogel, David
Lee, Steve R.
Wong, Steve
Wilcock, Diane
White, Mark L.
author_facet Corbin, John A.
Bhaskar, Vinay
Goldfine, Ira D.
Bedinger, Daniel H.
Lau, Angela
Michelson, Kristen
Gross, Lisa M.
Maddux, Betty A.
Kuan, Hua F.
Tran, Catarina
Lao, Llewelyn
Handa, Masahisa
Watson, Susan R.
Narasimha, Ajay J.
Zhu, Shirley
Levy, Raphael
Webster, Lynn
Wijesuriya, Sujeewa D.
Liu, Naichi
Wu, Xiaorong
Chemla-Vogel, David
Lee, Steve R.
Wong, Steve
Wilcock, Diane
White, Mark L.
author_sort Corbin, John A.
collection PubMed
description Previously we reported studies of XMetA, an agonist antibody to the insulin receptor (INSR). We have now utilized phage display to identify XMetS, a novel monoclonal antibody to the INSR. Biophysical studies demonstrated that XMetS bound to the human and mouse INSR with picomolar affinity. Unlike monoclonal antibody XMetA, XMetS alone had little or no agonist effect on the INSR. However, XMetS was a strong positive allosteric modulator of the INSR that increased the binding affinity for insulin nearly 20-fold. XMetS potentiated insulin-stimulated INSR signaling ∼15-fold or greater including; autophosphorylation of the INSR, phosphorylation of Akt, a major enzyme in the metabolic pathway, and phosphorylation of Erk, a major enzyme in the growth pathway. The enhanced signaling effects of XMetS were more pronounced with Akt than with Erk. In cultured cells, XMetS also enhanced insulin-stimulated glucose transport. In contrast to its effects on the INSR, XMetS did not potentiate IGF-1 activation of the IGF-1 receptor. We studied the effect of XMetS treatment in two mouse models of insulin resistance and diabetes. The first was the diet induced obesity mouse, a hyperinsulinemic, insulin resistant animal, and the second was the multi-low dose streptozotocin/high-fat diet mouse, an insulinopenic, insulin resistant animal. In both models, XMetS normalized fasting blood glucose levels and glucose tolerance. In concert with its ability to potentiate insulin action at the INSR, XMetS reduced insulin and C-peptide levels in both mouse models. XMetS improved the response to exogenous insulin without causing hypoglycemia. These data indicate that an allosteric monoclonal antibody can be generated that markedly enhances the binding affinity of insulin to the INSR. These data also suggest that an INSR monoclonal antibody with these characteristics may have the potential to both improve glucose metabolism in insulinopenic type 2 diabetes mellitus and correct compensatory hyperinsulinism in insulin resistant conditions.
format Online
Article
Text
id pubmed-3922975
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-39229752014-02-14 Improved Glucose Metabolism In Vitro and In Vivo by an Allosteric Monoclonal Antibody That Increases Insulin Receptor Binding Affinity Corbin, John A. Bhaskar, Vinay Goldfine, Ira D. Bedinger, Daniel H. Lau, Angela Michelson, Kristen Gross, Lisa M. Maddux, Betty A. Kuan, Hua F. Tran, Catarina Lao, Llewelyn Handa, Masahisa Watson, Susan R. Narasimha, Ajay J. Zhu, Shirley Levy, Raphael Webster, Lynn Wijesuriya, Sujeewa D. Liu, Naichi Wu, Xiaorong Chemla-Vogel, David Lee, Steve R. Wong, Steve Wilcock, Diane White, Mark L. PLoS One Research Article Previously we reported studies of XMetA, an agonist antibody to the insulin receptor (INSR). We have now utilized phage display to identify XMetS, a novel monoclonal antibody to the INSR. Biophysical studies demonstrated that XMetS bound to the human and mouse INSR with picomolar affinity. Unlike monoclonal antibody XMetA, XMetS alone had little or no agonist effect on the INSR. However, XMetS was a strong positive allosteric modulator of the INSR that increased the binding affinity for insulin nearly 20-fold. XMetS potentiated insulin-stimulated INSR signaling ∼15-fold or greater including; autophosphorylation of the INSR, phosphorylation of Akt, a major enzyme in the metabolic pathway, and phosphorylation of Erk, a major enzyme in the growth pathway. The enhanced signaling effects of XMetS were more pronounced with Akt than with Erk. In cultured cells, XMetS also enhanced insulin-stimulated glucose transport. In contrast to its effects on the INSR, XMetS did not potentiate IGF-1 activation of the IGF-1 receptor. We studied the effect of XMetS treatment in two mouse models of insulin resistance and diabetes. The first was the diet induced obesity mouse, a hyperinsulinemic, insulin resistant animal, and the second was the multi-low dose streptozotocin/high-fat diet mouse, an insulinopenic, insulin resistant animal. In both models, XMetS normalized fasting blood glucose levels and glucose tolerance. In concert with its ability to potentiate insulin action at the INSR, XMetS reduced insulin and C-peptide levels in both mouse models. XMetS improved the response to exogenous insulin without causing hypoglycemia. These data indicate that an allosteric monoclonal antibody can be generated that markedly enhances the binding affinity of insulin to the INSR. These data also suggest that an INSR monoclonal antibody with these characteristics may have the potential to both improve glucose metabolism in insulinopenic type 2 diabetes mellitus and correct compensatory hyperinsulinism in insulin resistant conditions. Public Library of Science 2014-02-12 /pmc/articles/PMC3922975/ /pubmed/24533136 http://dx.doi.org/10.1371/journal.pone.0088684 Text en © 2014 Corbin et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Corbin, John A.
Bhaskar, Vinay
Goldfine, Ira D.
Bedinger, Daniel H.
Lau, Angela
Michelson, Kristen
Gross, Lisa M.
Maddux, Betty A.
Kuan, Hua F.
Tran, Catarina
Lao, Llewelyn
Handa, Masahisa
Watson, Susan R.
Narasimha, Ajay J.
Zhu, Shirley
Levy, Raphael
Webster, Lynn
Wijesuriya, Sujeewa D.
Liu, Naichi
Wu, Xiaorong
Chemla-Vogel, David
Lee, Steve R.
Wong, Steve
Wilcock, Diane
White, Mark L.
Improved Glucose Metabolism In Vitro and In Vivo by an Allosteric Monoclonal Antibody That Increases Insulin Receptor Binding Affinity
title Improved Glucose Metabolism In Vitro and In Vivo by an Allosteric Monoclonal Antibody That Increases Insulin Receptor Binding Affinity
title_full Improved Glucose Metabolism In Vitro and In Vivo by an Allosteric Monoclonal Antibody That Increases Insulin Receptor Binding Affinity
title_fullStr Improved Glucose Metabolism In Vitro and In Vivo by an Allosteric Monoclonal Antibody That Increases Insulin Receptor Binding Affinity
title_full_unstemmed Improved Glucose Metabolism In Vitro and In Vivo by an Allosteric Monoclonal Antibody That Increases Insulin Receptor Binding Affinity
title_short Improved Glucose Metabolism In Vitro and In Vivo by an Allosteric Monoclonal Antibody That Increases Insulin Receptor Binding Affinity
title_sort improved glucose metabolism in vitro and in vivo by an allosteric monoclonal antibody that increases insulin receptor binding affinity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922975/
https://www.ncbi.nlm.nih.gov/pubmed/24533136
http://dx.doi.org/10.1371/journal.pone.0088684
work_keys_str_mv AT corbinjohna improvedglucosemetabolisminvitroandinvivobyanallostericmonoclonalantibodythatincreasesinsulinreceptorbindingaffinity
AT bhaskarvinay improvedglucosemetabolisminvitroandinvivobyanallostericmonoclonalantibodythatincreasesinsulinreceptorbindingaffinity
AT goldfineirad improvedglucosemetabolisminvitroandinvivobyanallostericmonoclonalantibodythatincreasesinsulinreceptorbindingaffinity
AT bedingerdanielh improvedglucosemetabolisminvitroandinvivobyanallostericmonoclonalantibodythatincreasesinsulinreceptorbindingaffinity
AT lauangela improvedglucosemetabolisminvitroandinvivobyanallostericmonoclonalantibodythatincreasesinsulinreceptorbindingaffinity
AT michelsonkristen improvedglucosemetabolisminvitroandinvivobyanallostericmonoclonalantibodythatincreasesinsulinreceptorbindingaffinity
AT grosslisam improvedglucosemetabolisminvitroandinvivobyanallostericmonoclonalantibodythatincreasesinsulinreceptorbindingaffinity
AT madduxbettya improvedglucosemetabolisminvitroandinvivobyanallostericmonoclonalantibodythatincreasesinsulinreceptorbindingaffinity
AT kuanhuaf improvedglucosemetabolisminvitroandinvivobyanallostericmonoclonalantibodythatincreasesinsulinreceptorbindingaffinity
AT trancatarina improvedglucosemetabolisminvitroandinvivobyanallostericmonoclonalantibodythatincreasesinsulinreceptorbindingaffinity
AT laollewelyn improvedglucosemetabolisminvitroandinvivobyanallostericmonoclonalantibodythatincreasesinsulinreceptorbindingaffinity
AT handamasahisa improvedglucosemetabolisminvitroandinvivobyanallostericmonoclonalantibodythatincreasesinsulinreceptorbindingaffinity
AT watsonsusanr improvedglucosemetabolisminvitroandinvivobyanallostericmonoclonalantibodythatincreasesinsulinreceptorbindingaffinity
AT narasimhaajayj improvedglucosemetabolisminvitroandinvivobyanallostericmonoclonalantibodythatincreasesinsulinreceptorbindingaffinity
AT zhushirley improvedglucosemetabolisminvitroandinvivobyanallostericmonoclonalantibodythatincreasesinsulinreceptorbindingaffinity
AT levyraphael improvedglucosemetabolisminvitroandinvivobyanallostericmonoclonalantibodythatincreasesinsulinreceptorbindingaffinity
AT websterlynn improvedglucosemetabolisminvitroandinvivobyanallostericmonoclonalantibodythatincreasesinsulinreceptorbindingaffinity
AT wijesuriyasujeewad improvedglucosemetabolisminvitroandinvivobyanallostericmonoclonalantibodythatincreasesinsulinreceptorbindingaffinity
AT liunaichi improvedglucosemetabolisminvitroandinvivobyanallostericmonoclonalantibodythatincreasesinsulinreceptorbindingaffinity
AT wuxiaorong improvedglucosemetabolisminvitroandinvivobyanallostericmonoclonalantibodythatincreasesinsulinreceptorbindingaffinity
AT chemlavogeldavid improvedglucosemetabolisminvitroandinvivobyanallostericmonoclonalantibodythatincreasesinsulinreceptorbindingaffinity
AT leestever improvedglucosemetabolisminvitroandinvivobyanallostericmonoclonalantibodythatincreasesinsulinreceptorbindingaffinity
AT wongsteve improvedglucosemetabolisminvitroandinvivobyanallostericmonoclonalantibodythatincreasesinsulinreceptorbindingaffinity
AT wilcockdiane improvedglucosemetabolisminvitroandinvivobyanallostericmonoclonalantibodythatincreasesinsulinreceptorbindingaffinity
AT whitemarkl improvedglucosemetabolisminvitroandinvivobyanallostericmonoclonalantibodythatincreasesinsulinreceptorbindingaffinity